Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) will participate in two investor conferences in November 2022. The Credit Suisse 31st Annual Healthcare Conference will include one-on-one meetings on November 8 in Rancho Palos Verdes, CA. The Jefferies London Healthcare Conference features a fireside chat on November 15 at 2:40 PM GMT and one-on-one meetings in London, UK. A webcast of the fireside chat will be available on Gracell's investor website for 30 days post-event. Gracell focuses on innovative cell therapies to treat cancer.

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two investor conferences in November 2022 as follows:

Credit Suisse 31^st Annual Healthcare Conference 2022
One-on-one meetings: Tuesday, November 8, 2022
Location: Rancho Palos Verdes, CA

Jefferies London Healthcare Conference 2022
Fireside Chat: November 15 at 2:40 pm GMT
One-on-one meetings: Tuesday, November 15, 2022
Location: London, UK

A webcast of the fireside chat will be available on the News and Events section of Gracell's investor website. A replay of the webcast will be available for 30 days following the event.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact

Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong 
gracie.tong@gracellbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-two-upcoming-investor-conferences-301656844.html

SOURCE Gracell Biotechnologies Inc.

FAQ

What conferences will Gracell Biotechnologies (GRCL) attend in November 2022?

Gracell Biotechnologies will attend the Credit Suisse 31st Annual Healthcare Conference on November 8 and the Jefferies London Healthcare Conference on November 15, 2022.

When is Gracell's fireside chat at the Jefferies London Healthcare Conference?

Gracell's fireside chat at the Jefferies London Healthcare Conference is scheduled for November 15, 2022, at 2:40 PM GMT.

Where will the Credit Suisse Healthcare Conference take place?

The Credit Suisse 31st Annual Healthcare Conference will be held in Rancho Palos Verdes, CA.

Is there a webcast available for Gracell's fireside chat?

Yes, a webcast of Gracell's fireside chat will be available on their investor website for 30 days after the event.

What is Gracell Biotechnologies' focus?

Gracell Biotechnologies is dedicated to developing highly effective and affordable cell therapies for cancer treatment.